Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • 15 hours ago

Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance

Beam Therapeutics NASDAQ: BEAM reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvements in fasting tolerance and reductions in cornstarch supplementation among the first six treated patients.

MarketBeat • Oct 27, 2026

Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript

Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript

Seeking Alpha • Oct 27, 2026

Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress

In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment  Safety Profile of BEAM-301 Consistent with LNP-Based Therapies Beam Plans to Engage FDA on Potential Path to Approval; Enrollment in 60 mg Dose Cohort Underway Company to Host Investor Webcast Today, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.

GlobeNewsWire • Oct 27, 2026

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

Cathie Wood owns Beam shares worth roughly $220 million, at the stock's current price. All of the company's revenue is collaboration revenue.

The Motley Fool • Oct 18, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • Oct 15, 2026

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.

GlobeNewsWire • Oct 13, 2026

Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse

Short sellers are betting heavily against 10 stocks, and the fuse is getting shorter. Each one has more than 38% of its float sold short, with market caps above $2 billion and average daily volume above 1 million shares, according to Benzinga Pro screener data as of Oct. 12.

Benzinga • Oct 13, 2026

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while Risto-cel's blockbuster potential is now downgraded. AI-driven competition, such as Anthropic, is unlikely to disrupt BEAM in the near term; partnerships with AI firms could become a future catalyst.

Seeking Alpha • Sep 29, 2026

Squeeze Watch: 10 Stocks With Over 33% Short Interest

Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.

Benzinga • Sep 25, 2026